公开(公告)号：US11167032B2

公开(公告)日：2021-11-09

申请号：US15956099

申请日：2018-04-18

Applicant: Variation Biotechnologies Inc.

Inventor： Marc J. Kirchmeier ,  David E. Anderson

IPC: A61K39/12 ,  A61K47/14 ,  A61K39/395 ,  C07K16/32 ,  A61K39/00 ,  A61K39/165 ,  A61K39/20 ,  A61K39/295 ,  A61K47/24 ,  A61K47/28 ,  C12N7/00 ,  A61K9/127

Abstract: The present disclosure provides inter alia compositions that comprise therapeutic agents (e.g., live attenuated viral antigens, therapeutic proteins, etc.) and a lipid component. The lipid component may comprise or consist of different types of lipid or lipids as described herein. In some embodiments the therapeutic agents are thermolabile. The present disclosure also provides methods for preparing compositions, including the aforementioned compositions (e.g., melt methods and spray injection methods among others).

公开(公告)号：US10161010B2

公开(公告)日：2018-12-25

申请号：US15991044

申请日：2018-05-29

Applicant: Variation Biotechnologies Inc.

Inventor： David E. Anderson ,  Jasminka Bozic ,  Barthelemy Ontsouka

IPC: C12Q1/70 ,  G01N33/50 ,  G01N33/68 ,  A61K39/12 ,  A61K39/00

Abstract: The present disclosure provides methods useful for determining levels of HCMV infection in host cells and, by extension, determining levels of neutralizing antibodies present in a sample. The present disclosure encompasses the recognition that HCMV viruses that have a fluorescent moiety permit detection of viral infection (e.g., by assessing fluorescence in cells after contacting the host cell with the virus). In some embodiments, levels of HCMV infection are determined by fluorescence detection where the virus has been preincubated with a test sample (e.g., a serum sample) from a subject. In some embodiments, the subject has been administered a candidate HCMV vaccine.

公开(公告)号：US20180274044A1

公开(公告)日：2018-09-27

申请号：US15991044

申请日：2018-05-29

Applicant: Variation Biotechnologies Inc.

Inventor： David E. Anderson ,  Jasminka Bozic ,  Barthelemy Ontsouka

IPC: C12Q1/70 ,  A61K39/12 ,  G01N33/50 ,  G01N33/68 ,  A61K39/00

CPC classification number: C12Q1/70 ,  A61K39/12 ,  A61K2039/5258 ,  A61K2039/55505 ,  A61K2039/70 ,  C12N2710/16134 ,  G01N33/5044 ,  G01N33/6854 ,  G01N2333/045 ,  G01N2469/20

Abstract: The present disclosure provides methods useful for determining levels of HCMV infection in host cells and, by extension, determining levels of neutralizing antibodies present in a sample. The present disclosure encompasses the recognition that HCMV viruses that have a fluorescent moiety permit detection of viral infection (e.g., by assessing fluorescence in cells after contacting the host cell with the virus). In some embodiments, levels of HCMV infection are determined by fluorescence detection where the virus has been preincubated with a test sample (e.g., a serum sample) from a subject. In some embodiments, the subject has been administered a candidate HCMV vaccine.

公开(公告)号：US20180256723A1

公开(公告)日：2018-09-13

申请号：US15810575

申请日：2017-11-13

Applicant: Variation Biotechnologies Inc.

Inventor： David E. Anderson

IPC: A61K47/28 ,  A61K47/24 ,  A61K39/12 ,  A61K39/205 ,  A61K39/39 ,  A61K47/14 ,  C12N7/00 ,  A61K39/00

CPC classification number: A61K47/28 ,  A61K39/12 ,  A61K39/205 ,  A61K39/39 ,  A61K47/14 ,  A61K47/24 ,  A61K2039/55555 ,  A61K2039/55566 ,  C12N7/00 ,  C12N2760/20134 ,  C12N2760/20171 ,  Y02A50/466

Abstract: The present disclosure provides compositions and methods useful for treating viral infections. As described herein, the compositions and methods are based on the development of immunogenic compositions that include an inactivated virus in combination with a non-ionic surfactant vesicle (NISV). In certain embodiments at least a portion of the antigen present in the composition is physically associated with the NISV. In certain embodiments the compositions are lyophilized and subsequently rehydrated after a period of storage. In certain embodiments the rehydrated compositions exhibit greater potency as compared to otherwise equivalent compositions that lack the NISV. In certain embodiments the lyophilized compositions are stored at temperatures in excess of 8° C. prior to rehydration. In certain embodiments, the rehydrated compositions exhibit greater potency as compared to otherwise equivalent compositions that lack the NISV and that were also stored at temperatures in excess of 8° C. prior to rehydration. In certain embodiments the antigen is taken from a licensed vaccine and the administered dose of antigen is less than the standard human dose for the licensed vaccine.

公开(公告)号：US10006096B2

公开(公告)日：2018-06-26

申请号：US14387870

申请日：2013-03-27

Applicant: VARIATION BIOTECHNOLOGIES, INC.

Inventor： David E. Anderson ,  Jasminka Bozic ,  Barthelemy Ontsouka

IPC: C12Q1/70 ,  G01N33/50 ,  G01N33/68 ,  A61K39/12 ,  A61K39/00

CPC classification number: C12Q1/70 ,  A61K39/12 ,  A61K2039/5258 ,  A61K2039/55505 ,  A61K2039/70 ,  C12N2710/16134 ,  G01N33/5044 ,  G01N33/6854 ,  G01N2333/045 ,  G01N2469/20

Abstract: The present disclosure provides methods useful for determining levels of HCMV infection in host cells and, by extension, determining levels of neutralizing antibodies present in a sample. The present disclosure encompasses the recognition that HCMV viruses that have a fluorescent moiety permit detection of viral infection (e.g., by assessing fluorescence in cells after contacting the host cell with the virus). In some embodiments, levels of HCMV infection are determined by fluorescence detection where the virus has been preincubated with a test sample (e.g., a serum sample) from a subject. In some embodiments, the subject has been administered a candidate HCMV vaccine.

公开(公告)号：US20140356399A1

公开(公告)日：2014-12-04

申请号：US14371935

申请日：2013-01-11

Applicant: Variation Biotechnologies, Inc.

Inventor： David E. Anderson

IPC: A61K47/28 ,  C12N7/00 ,  A61K47/24 ,  A61K39/205 ,  A61K47/14

CPC classification number: A61K47/28 ,  A61K39/12 ,  A61K39/205 ,  A61K39/39 ,  A61K47/14 ,  A61K47/24 ,  A61K2039/55555 ,  A61K2039/55566 ,  C12N7/00 ,  C12N2760/20134 ,  C12N2760/20171 ,  Y02A50/466

Abstract: The present disclosure provides compositions and methods useful for treating viral infections. As described herein, the compositions and methods are based on the development of immunogenic compositions that include an inactivated virus in combination with a non-ionic surfactant vesicle (NISV). In certain embodiments at least a portion of the antigen present in the composition is physically associated with the NISV. In certain embodiments the compositions are lyophilized and subsequently rehydrated after a period of storage. In certain embodiments the rehydrated compositions exhibit greater potency as compared to otherwise equivalent compositions that lack the NISV. In certain embodiments the lyophilized compositions are stored at temperatures in excess of 8° C. prior to rehydration. In certain embodiments the rehydrated compositions exhibit greater potency as compared to otherwise equivalent compositions that lack the NISV and that were also stored at temperatures in excess of 8° C. prior to rehydration. In certain embodiments the antigen is taken from a licensed vaccine and the administered dose of antigen is less than the standard human dose for the licensed vaccine.

Abstract translation: 本公开提供了可用于治疗病毒感染的组合物和方法。 如本文所述，组合物和方法基于包括与非离子表面活性剂囊泡（NISV）组合的灭活病毒的免疫原性组合物的开发。 在某些实施方案中，组合物中存在的至少一部分抗原与NISV物理相关。 在某些实施方案中，将组合物冻干并随后在储存一段时间后再水化。 在某些实施方案中，与缺乏NISV的其它等同组合物相比，再水化组合物表现出更大的效力。 在某些实施方案中，冻干组合物在再水化之前储存在超过8℃的温度下。 在某些实施方案中，与缺乏NISV的其它等同组合物相比，再水合组合物显示出更大的效力，并且在再水合之前也在超过8℃的温度下储存。 在某些实施方案中，抗原是从经许可的疫苗获得的，并且所给予的抗原剂量小于许可疫苗的标准人剂量。

公开(公告)号：US20140328876A1

公开(公告)日：2014-11-06

申请号：US14359033

申请日：2012-11-16

Applicant: VARIATION BIOTECHNOLOGIES INC.

Inventor： Maura Ellen Campbell

IPC: A61K39/39 ,  A61K39/29 ,  A61K39/00 ,  A61K39/02 ,  A61K39/112 ,  A61K39/21 ,  C07H15/12 ,  A61K39/145

CPC classification number: A61K39/39 ,  A61K9/0019 ,  A61K9/127 ,  A61K9/19 ,  A61K39/00 ,  A61K39/0275 ,  A61K39/099 ,  A61K39/107 ,  A61K39/12 ,  A61K39/145 ,  A61K39/21 ,  A61K39/29 ,  A61K39/292 ,  A61K2039/55555 ,  A61K2039/55572 ,  C07H13/04 ,  C07H13/06 ,  C07H15/12 ,  C12N2760/16034 ,  C12N2760/16134 ,  C12N2760/16234 ,  Y02A50/484

Abstract: In one aspect, the present disclosure provides compounds of formulae (I) and (II). In another aspect, a compound of formula (I) or (II) is formulated into compositions with an antigen, optionally with a vesicle. In some embodiments, compositions are administered intramuscularly.

Abstract translation: 一方面，本发明提供式（I）和（II）的化合物。 在另一方面，式（I）或（II）的化合物与抗原配制成组合物，任选具有囊泡。 在一些实施方案中，肌内施用组合物。

公开(公告)号：US11167033B2

公开(公告)日：2021-11-09

申请号：US15810575

申请日：2017-11-13

Applicant: Variation Biotechnologies Inc.

Inventor： David E. Anderson

IPC: A61K47/28 ,  A61K39/12 ,  A61K39/39 ,  A61K39/205 ,  A61K47/14 ,  C12N7/00 ,  A61K47/24 ,  A61K39/00

Abstract: The present disclosure provides compositions and methods useful for treating viral infections. As described herein, the compositions and methods are based on the development of immunogenic compositions that include an inactivated virus in combination with a non-ionic surfactant vesicle (NISV). In certain embodiments at least a portion of the antigen present in the composition is physically associated with the NISV. In certain embodiments the compositions are lyophilized and subsequently rehydrated after a period of storage. In certain embodiments the rehydrated compositions exhibit greater potency as compared to otherwise equivalent compositions that lack the NISV. In certain embodiments the lyophilized compositions are stored at temperatures in excess of 8° C. prior to rehydration. In certain embodiments, the rehydrated compositions exhibit greater potency as compared to otherwise equivalent compositions that lack the NISV and that were also stored at temperatures in excess of 8° C. prior to rehydration. In certain embodiments the antigen is taken from a licensed vaccine and the administered dose of antigen is less than the standard human dose for the licensed vaccine.

公开(公告)号：US20210069321A1

公开(公告)日：2021-03-11

申请号：US17014028

申请日：2020-09-08

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA ,  VARIATION BIOTECHNOLOGIES INC.

Inventor： Kirsten SCHNEIDER-OHRUM ,  David Evander ANDERSON

IPC: A61K39/245 ,  A61K39/21 ,  A61K39/39 ,  A61K9/127

Abstract: The present disclosure provides compositions and methods useful for treating Glioblastoma Multiforme (GBM) which comprise virus-like particles (VLPs) comprising murine leukemia virus (MLV) core proteins and the human cytomegalovirus epitopes, gB and pp65, formulated with an adjuvant comprising a saponin and a TLR4 agonist.

公开(公告)号：US10456460B2

公开(公告)日：2019-10-29

申请号：US15795678

申请日：2017-10-27

Applicant: Variation Biotechnologies Inc.

Inventor： David E. Anderson ,  Anne-Catherine Fluckiger

IPC: A61K39/12 ,  C12N7/00 ,  C07K14/005 ,  A61K39/00

Abstract: The present disclosure provides compositions and methods useful for preventing and treating Zika virus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more Zika epitopes, such as, for example, from Zika envelope glycoprotein E and the Zika structural protein NS1 including variants thereof.